Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Higher recipient pre-transplant FOXP3 mRNA expression is associated with acute leukaemia relapse after HSCT

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Inactivating BTK mutations in large B-cell lymphoma in a real-world cohort: Strong correlation with BCL2 translocation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Axillary lymph nodes on PET in Hodgkin lymphoma after COVID-19 vaccination

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Facilitating EMA binding test performance using fluorescent beads combined with next-generation sequencing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype-genotype study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Fatal JC-virus Granular Cerebellar Neuronopathy in a Patient Diagnosed with ALPS and Hypogammaglobulinemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The effect of higher FOXP3 mRNA expression by recipient pre-transplant CD4+ T cells on leukaemia relapse was analysed in a series of 106 patients who received allogeneic haematopoietic stem cell transplantation after myeloablative conditioning with or without antithymocyte globulin (ATG) due to acute leukaemia in 1st or 2nd complete remission. FOXP3 mRNA was measured by qPCR in purified CD4+ T cells from blood obtained before conditioning. Higher FOXP3 mRNA expression was associated with an increased relapse risk when conditioning included ATG (n = 43, hazard ratio [HR] 11.0 [2.50-48.4], p = 0.00001). No effect was observed in patients not receiving ATG (HR 0.95 [0.53-1.81]).

OriginalsprogEngelsk
TidsskriftEJHaem
Vol/bind3
Udgave nummer3
Sider (fra-til)975-979
Antal sider5
ISSN2688-6146
DOI
StatusUdgivet - aug. 2022

Bibliografisk note

© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

ID: 84432890